Oct. 08 2024
Source Page: Elafibranor approved as first medicine to treat adults with a rare liver disease known as primary biliary cholangitisFound: Elafibranor approved as first medicine to treat adults with a rare liver disease known as primary biliary
Nov. 28 2011
Source Page: A census of medical workforce and infrastructure for liver disease strategy: summary of findings (final 2011). 20 p.Found: A census of medical workforce and infrastructure for liver disease strategy: summary of findings (final
Jun. 27 2011
Source Page: Hepatitis C in the UK. 102 p.Found: disease •Liver-related deaths (defined as either viral hepatitis, liver cancer, alcoholic liver disease
Sep. 18 2024
Source Page: Service specification: hepato-pancreatic biliary (HPB) – primary liver, secondary liver, perihilar biliary tract and gallbladder cancersFound: Service specification: hepato-pancreatic biliary (HPB) – primary liver, secondary liver, perihilar biliary
Mar. 07 2008
Source Page: Hepatitis C in England: the Health Protection Agency annual report 2007. 72 p.Found: Hepatitis C in England: the Health Protection Agency annual report 2007. 72 p.
Nov. 08 2011
Source Page: Hepatitis C in the UK. 97 p.Found: As Blackpool has been ident ified as having some of the worst liver -related health inequalities, the
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to support the detection of liver disease in Washington and Sunderland West constituency.
Answered by Andrew Stephenson
The Northern Cancer Alliance (NCA) is supporting services to enable the early detection of liver disease across the North East and North Cumbria (NENC) Integrated Care Board (ICB), including in the Washington and Sunderland West Constituency. The focus of work has been to support liver services across NENC to invite more than 80% of patients with cirrhosis, a type of liver disease, to monthly ultrasound surveillance. For 2024/25, the NCA has invested just over £200,000 into trusts across NENC to help improve their monitoring systems for cirrhosis patients.
The NENC ICB is also enrolled in a Community Liver Health Check pilot in Newcastle, being delivered by the system’s Hepatitis C Operational Delivery Networks. This will provide FibroScans in one stop community clinics where patients have relevant blood testing, liver ultrasound, and other investigations, as required. The pilot has expanded into North Tyneside and when resources allow, they intend to develop additional clinics across the area.
Jun. 11 2024
Source Page: Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]Found: Summary form National Institute for Health and Care Excellence Page 1 of 13 Consultation
Asked by: Gregory Campbell (Democratic Unionist Party - East Londonderry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an estimate of expected liver cancer mortality rates by the end of 2025.
Answered by Andrew Stephenson
No estimate has been made of expected liver cancer mortality rates by the end of 2025. The care of and treatment for patients with cancer, including liver cancer, is a priority for the Government. Early diagnosis of liver cancer is critical to improving rates of survival. NHS England’s Early Diagnosis of Liver Cancer Programme is contributing to the NHS Long Term Plan’s commitment to diagnose 75% of all cancers at stage one or two by 2028. This programme includes three workstreams: improving liver surveillance programmes; community liver health checks pilots; and primary care pilots. Identifying those at risk and ensuring patients are tested and referred to a surveillance programme, where necessary, will lead to improved patient outcomes.
Asked by: Alison Thewliss (Scottish National Party - Glasgow Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the implications for her policies of the development of intelligent liver function tests by the University of Dundee; and if she will make it her policy to increase the rollout of these tests in areas with the highest levels of liver disease in England.
Answered by Andrew Stephenson
The Government is working with the National Health Service to support earlier diagnosis of liver disease, and to identify patients at risk. This includes plans agreed as part of the £2.3 billion diagnostics transformation programme, to upgrade the digital capabilities of laboratories across the country and ensure that they have the capability required to offer Intelligent Liver Function Tests (iLFTs).
NHS England is reviewing the liver fibrosis pathways, and looking at developing a diagnosis pathway starting in primary care that will make use of both laboratory-based tests, such as iLFTs, and community diagnostic centres. The Government will make a further assessment of this work once it is complete, including the benefits of an increased rollout of iLFTs across England.